Monitor for insider trading patterns (Form 4 filings) from reporting officer as share lock-up restrictions from the merger may expire. The filing itself carries no immediate trading signal.
Price Chart
Executive Summary
Saira Ramasastry filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing option grants received in connection with the merger between Sensei Biotherapeutics and Faeth Therapeutics. This is a routine administrative filing triggered by the merger and indicates no new capital deployment or change in corporate strategy.
Key Facts
- Form 3 filed by Saira Ramasastry on 2026-06-16, reporting a period of 2026-06-12
- Discloses two employee stock options: one for 8,718 shares at $1.16 expiring 2036-01-24 and one for 5,929 shares at $5.22 expiring 2034-05-10
- Options were received in exchange for Faeth Therapeutics options pursuant to the February 17, 2026 merger agreement
- The first option vests in 24 equal monthly installments starting August 2022; the second option is fully vested
- Merger involved Sapphire First Merger Sub and Sapphire Second Merger Sub
Financial Impact
No new capital raised or deployed; reporting of option grants with aggregate exercise value of approximately $41K based on disclosed exercise prices
Risk Factors
- Potential future insider selling post-lockup expiration could pressure stock
- Micro-cap biotech with $19M market cap faces high cash-burn risk without disclosed revenue or pipeline catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001547959-26-000014 |
| Document: 0001547959-26-000014-index-headers.html | 0001547959-26-000014 |
| Document: 0001547959-26-000014-index.html | 0001547959-26-000014 |
| Document: 0001547959-26-000014.txt | 0001547959-26-000014 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 16, 2026 19w ago | 3 | $13.86 | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | 8-K | $13.04 | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | EFFECT | $13.04 | awaiting T+5 | — | — |
Jun 10, 2026 19w ago | S-3/A | $10.79 $13.85 | ▲ +28.36% | ▲ +27.93% | — |
Jun 10, 2026 19w ago | 8-K | $10.79 $13.85 | ▲ +28.36% | ▲ +27.93% | — |
Jun 2, 2026 21w ago | 10-K/A | $16.10 $12.63 | ▼ −21.53% | ▼ −18.56% | — |
Jun 2, 2026 21w ago | S-3/A | $16.10 $12.63 | ▲ +21.53% | ▲ +18.56% | — |
Jun 1, 2026 21w ago | Insider Cluster | $16.10 $12.63 | ▲ +21.53% | ▲ +18.56% | — |
May 22, 2026 22w ago | DEFA14A | $16.47 $19.79 | ▲ +20.16% | ▲ +19.07% | — |
May 22, 2026 22w ago | 8-K | $16.47 $19.79 | ▲ +20.16% | ▲ +19.07% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers